InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
InMed Pharmaceuticals Q1 EPS $(0.36) Up From $(0.46) YoY
InMed Announces Share Consolidation in Connection with Proposed Merger
InMed Announces CVR Distribution Record Date in Connection with Proposed Merger
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
INM Stock Alert: What to Know as InMed, Mentari Announce Merger
/C O R R E C T I O N -- InMed Pharmaceuticals/
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline
InMed Pharmaceuticals Amends Preferred Investment Options
UPDATE: InMed Pharmaceuticals To Merge With Mentari Therapeutics In All-Stock Deal Backed By $290M Private Placement, Combined Company Valued At $421.4M; InMed Shareholders to Own 1.51% Stake
InMed Pharmaceuticals To Merge With Mentari Therapeutics
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.